Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1994 3
1995 2
1996 5
1997 4
1998 13
1999 6
2000 14
2001 12
2002 13
2003 17
2004 20
2005 23
2006 29
2007 21
2008 39
2009 36
2010 43
2011 40
2012 35
2013 42
2014 34
2015 32
2016 27
2017 19
2018 22
2019 10
2020 12
2021 12
2022 16
2023 19
2024 15
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

562 results

Results by year

Filters applied: . Clear all
Page 1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. Among authors: groothoff jw. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J. Groothoff JW, et al. Nat Rev Nephrol. 2023 Mar;19(3):194-211. doi: 10.1038/s41581-022-00661-1. Epub 2023 Jan 5. Nat Rev Nephrol. 2023. PMID: 36604599 Review.
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Michael M, et al. Among authors: groothoff jw. Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14. Am J Kidney Dis. 2023. PMID: 35843439 Free article. Clinical Trial.
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators. Baum MA, et al. Among authors: groothoff j. Kidney Int. 2023 Jan;103(1):207-217. doi: 10.1016/j.kint.2022.07.025. Epub 2022 Aug 22. Kidney Int. 2023. PMID: 36007597 Free article. Clinical Trial.
Lessons learned from the ESPN/ERA-EDTA Registry.
Harambat J, Bonthuis M, Groothoff JW, Schaefer F, Tizard EJ, Verrina E, van Stralen KJ, Jager KJ. Harambat J, et al. Among authors: groothoff jw. Pediatr Nephrol. 2016 Nov;31(11):2055-64. doi: 10.1007/s00467-015-3238-8. Epub 2015 Oct 24. Pediatr Nephrol. 2016. PMID: 26498279 Review.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators. Frishberg Y, et al. Among authors: groothoff jw. Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. Clin J Am Soc Nephrol. 2021. PMID: 33985991 Free PMC article. Clinical Trial.
Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries.
Gimpel C, Fieuws S, Hofstetter J, Pitcher D, Vanmeerbeek L, Haeberle S, Dachy A, Massella L, Seeman T, Ranchin B, Allard L, Bacchetta J, Bayrakci US, Becherucci F, Perez-Beltran V, Besouw M, Bialkevich H, Boyer O, Canpolat N, Chauveau D, Çiçek N, Conlon PJ, Devuyst O, Dossier C, Fila M, Flögelová H, Godron-Dubrasquet A, Gokce I, Nguyen-Tang EG, González-Rodríguez JD, Guffens A, Grandaliano G, Heidet L, Jankauskiene A, Levart TK, Knebelmann B, König JC, La Scola C, Leone VF, Leroy V, Litwin M, Lucchetti L, Lungu AC, Marzuillo P, Mastrangelo A, Miklaszewska M, Montini G, Nobili F, Obrycki L, Papizh S, Paripović A, Paripović D, Peruzzi L, Raes A, Saygili S, Spasojević B, Simon T, Szczepańska M, Trepiccione F, Varda NM, Westland R, Yüksel S, Zaluska-Lesniewska I, Tenebaum J, Mustafa R, Mallett AJ, Guay-Woodford LM, Gale DP, Böckenhauer D, Liebau MC, Schaefer F, Mekahli D; RaDaR ADPKD Rare Disease Group; ERKReg Collaborators; ADPedKD Collaborators. Gimpel C, et al. Kidney Int. 2025 Jul;108(1):105-118. doi: 10.1016/j.kint.2025.02.026. Epub 2025 Mar 21. Kidney Int. 2025. PMID: 40122340 Free article.
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
Reijman MD, Tromp TR, Hutten BA, Hovingh GK, Blom DJ, Catapano AL, Cuchel M, Dann EJ, Gallo A, Hudgins LC, Raal FJ, Ray KK, Sadiq F, Soran H, Groothoff JW, Wiegman A, Kusters DM; Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC); Children with Homozygous Hypercholesterolemia on Lipoprotein Apheresis: an International Registry (CHAIN) consortia. Reijman MD, et al. Among authors: groothoff jw. Lancet Child Adolesc Health. 2024 Jul;8(7):491-499. doi: 10.1016/S2352-4642(24)00073-7. Epub 2024 May 14. Lancet Child Adolesc Health. 2024. PMID: 38759658 Free PMC article.
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.
Saland JM, Lieske JC, Groothoff JW, Frishberg Y, Shasha-Lavsky H, Magen D, Moochhala SH, Simkova E, Coenen M, Hayes W, Hogan J, Sellier-Leclerc AL, Willey R, Gansner JM, Hulton SA. Saland JM, et al. Among authors: groothoff jw. Kidney Int Rep. 2024 Apr 26;9(7):2037-2046. doi: 10.1016/j.ekir.2024.04.048. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081738 Free PMC article.
562 results